Brian Achenbach

All filings by Brian Achenbach on record concern Mustang Bio, Inc., in the capacity of chief executive. In total, 17 filings cover trades dated from 2 February 2018 to 14 December 2021.

Both buying and selling appear: 3 purchases worth €9,218, against 8 sales worth €73k. Taken together, the sales exceed the purchases by €64k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Other entries cover 6 share grants. So far in 2021, the count stands at no purchases and 8 sales.

Half of the purchases are above €3,724 and half below. Clusters matter here: 3 out of 3 purchases overlapped with buying by a colleague within 30 days. Purchases made close together by different insiders form what is called a cluster.

The record was last updated on 16 December 2021 with an open-market sale (€7,093) in Mustang Bio, Inc. The most recent open-market purchase was published on 3 December 2018, 2,898 days ago. The median gap between a trade and its publication by SEC (Form 4) is 55 days. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.